Study details
Enrolling now
SAfety of Regional Citrate Anticoagulation (SARCA Study)
Fresenius Medical Care North America
NCT IDNCT05339139ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
50
Study length
about 1.8 years
Ages
18+
Locations
10 sites in AR, FL, MA +5
What this study is about
Researchers are testing the safety of a new way to give citrate anticoagulation during dialysis for people with kidney failure. The treatment involves using a special system called multiFiltratePRO. The trial will last about 653 days and involve approximately 50 adults.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Dialysis
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Symptoms and systemic ionized calcium level, Symptoms and total-to-ionized calcium ratio
Body systems
Renal